SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverHIK.L
HealthcareLSEGBP

Hikma Pharmaceuticals

£0012345678900123456789.0012345678900123456789+5.7%
52w low (est.) £12.52£19.43 52w high (est.)
Peers
Market data
Market cap
£3.33B
Beta (vs market)
0.65
Sector
Healthcare
Valuation
P/E ratio
11.6x
DCF fair value
£34.85
Margin of safety
+124.7%
Forward P/E
8.6x
PEG ratio
1.71
Dividend yield
3.82%
Quality & efficiency
Moat score
56/100
Return on equity
16.5%
Profit margin
12.0%
Debt / equity
0.62
Growth & analysts
Revenue growth (YoY)
+8.5%
Analyst target
£18.95
Target upside
+22.2%
Analysts covering
11

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Valuation

ValueGrowthProfitHealthIncome65QUALITY
Overall Rating
79
Strong Buy
Strong Buy
Moat Score56
DCF Intrinsic Value
£34.85+124.7% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
£3.33B
P/E Ratio
11.6
Dividend Yield
3.82%
Revenue Growth
+8.5%
Profit Margin
12.0%
ROE
16.5%
Debt / Equity
0.62
Beta
0.65
ValueDividend Aristocrats
vs Healthcare sector:P/E 12 vs 28 · cheaperMoat 56 vs 7Yield 3.82% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · HIK.L